Calibrate vs ResMed
Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health company delivering one-year GLP-1 programs with semaglutide or tirzepatide plus behavioral coaching, nutrition, and activity guidance via physician-supervised telehealth.
About
Calibrate is a metabolic health company that delivers a one-year weight loss program combining GLP-1 receptor agonist medications — including semaglutide and tirzepatide — with behavioral coaching, food education, sleep guidance, and activity programming through a telehealth platform. The program's clinical foundation differentiates it from consumer weight loss apps and traditional diet programs by centering medication management under physician supervision as the primary intervention, with lifestyle coaching structured to support long-term habit change alongside pharmaceutical treatment. Calibrate's approach reflects the clinical consensus that obesity is a chronic metabolic disease requiring medical treatment rather than a lifestyle choice addressable through willpower alone.
ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.
About
ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.